Should biologics for psoriasis be interrupted in the era of COVID-19?

Lebwohl, Mark; Rivera-Oyola, Ryan; Murrell, Dédée F.

doi:10.1016/j.jaad.2020.03.031

Cited by 150 publications

(188 citation statements)

References 4 publications

Supporting

Mentioning

170

Contrasting

Unclassified

Order By: Relevance

“…Biologics have revolutionized the treatment and management of chronic dermatological disorders, but they also have increased the rate of airway infections, especially for psoriasis and hidradenitis suppurativa 12,13,36,37 . Conversely, in a recent meta‐analysis Zayed and colleagues did not find an increased risk of airway infections in AD patients with asthma undergoing dupilumab 38 .…”

Section: Discussionmentioning

confidence: 99%

COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey duringRED‐ZONEdeclaration

Bragazzi

Riccò

Pacifico

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

SARS-CoV-2 become pandemics and there is still a dearth of data about its the potentially among dermatological patients under biologics. We aimed to assess health literacy, disease knowledge, treatment dissatisfaction and biologics attitudes toward COVID-19. We performed a cross-sectional, questionnaire-based survey on 98/105 consecutive dermatological patients treated with biologics-51 suffering from plaque psoriasis, 22 from atopic dermatitis, and 25 from hidradenitis suppurativa. An ad hoc, validated questionnaire has 44 items investigating the following domains: knowledge of COVID-19 related to (a) epidemiology, (b) pathogenesis, (c) clinical symptoms, (d) preventive measures, and (e) attitudes. Patients data and questionnaires were collected. Despite only 8.1% thought that biologics may increase the risk of COVID-19, 18.4% and 21.4% of the patients were evaluating the possibility to discontinue or modify the dosage of the current biologic therapy, respectively. Globally, male patients (P = .001) with higher scholarity level (P = .005) displayed higher knowledge of COVID-19. Patients with lower DLQI (P = .006), longer disease duration (P = .051) and lower scholarity (P = .007) have thought to discontinue/modify autonomously their biologic therapy. At the multivariate logistic regression, only the knowledge of epidemiology and preventive measures resulted independent predictors of continuation vs discontinuation and modification vs no modification, respectively. Dermatologists should promote COVID-19 knowledge to prevent biologics disruption.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID‐19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey duringRED‐ZONEdeclaration

Bragazzi

Riccò

Pacifico

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Patients were, however, discouraged from abruptly discontinuing their IMT, including biologic agents, as discontinuation of some biologics can result in loss of response when treatments are reintroduced or even result in the formation of antibodies to the discontinued biologic. 56 Urgent cases which require clinic visits are those having active posterior or panuveitis or active uveitic complications, such as inflammatory choroidal neovascular membrane or cystoid macular oedema. The aims of these visits are first to assess and treat the sight-threatening uveitic conditions or complications, and second to provide patients with a long-term treatment protocol.…”

Section: Open Accessmentioning

confidence: 99%

Ophthalmology practice during the COVID-19 pandemic

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo present an established practice protocol for safe and effective hospital-setting ophthalmic practice during the coronavirus disease 2019 (COVID-19) pandemic.Methods and AnalysisLiterature was reviewed to identify articles relevant to COVID-19 pandemic and ophthalmology. The following keywords were used: COVID-19, SARS-CoV-2 and telemedicine, combined with eye, ophthalmology, conjunctivitis and tears. Data were extracted from the identified manuscripts and discussed among subspecialists to obtain consensus evidence-based practice.ResultsA protocol for ophthalmic practice in the era of COVID-19 pandemic was established. The protocol covered patient screening, clinic flow, required personal protective equipment and modifications of ophthalmic equipment for improved safety.ConclusionImportant literature emerged with respect to the practice of ophthalmology in the era of COVID-19. An evidence-based ophthalmic practice protocol was established and should be modified in the future to accommodate new insights on the COVID-19 pandemic.

show abstract

“…There is no available evidence that supports discontinuation of biologic treatment of psoriasis for most patients simply because of the risk of infection [24]. According to the results of randomized clinical trials of biological agents in psoriasis, the rates of nasopharyngitis and upper respiratory tract infections are similar to placebo [25].…”

mentioning

confidence: 99%